About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 109 entries.

Entries by Haley Chartres

SPP Now Open

November 8, 2022 in , , , /by

Botanix’s recently announced Share Purchase Plan (SPP) to raise up to A$3 million is now open for eligible AU/NZ shareholders. The SPP opens today, 9 November 2022 and will remain open until 8:00pm AEDT on Wednesday, 23 November 2022 (unless extended or withdrawn).  As the SPP is only open for two weeks, eligible shareholders are […]

Promotion of Dr Howie McKibbon to Chief Operating Officer

October 20, 2022 in , , , /by

Botanix has announced the promotion of Dr Howie McKibbon to the role of Chief Operating Officer, from his current position as Chief Commercial Officer. Howie has more than 20 years of leadership experience in the pharmaceutical industry. He has launched 15 products including 11 in dermatology, and managed over 30 dermatology products. Importantly too, he […]

Research Report by Euroz Hartleys – 14 October 2022

October 14, 2022 in , , /by

Botanix is pleased to share a recent analyst report published by Euroz Hartleys following last week’s announcement of positive results from our BTX 1702 Phase 1b/2 clinical trial for rosacea.  Analyst Seth Lizee noted: “We believe the rosacea treatment universe is prime for disruption, with a gap in the market for drugs that can deliver […]

Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea

October 12, 2022 in , , /by

Botanix has released positive data from its BTX1702 rosacea clinical study.  The Phase 1b/2 randomised, double-blind vehicle-controlled study examined the effects Botanix’s CBD formulation BTX 1702 in adults with moderate to severe papulopustular rosacea over an 8-week treatment period. The study tested two different concentrations of BTX 1702 topical gel – 10% and 20% – […]

Botanix submits NDA for FDA approval of Sofpironium Bromide

September 26, 2022 in , , /by

Botanix has today announced the submission of a New Drug Application to the FDA for approval of Sofpironium Bromide for the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating). Phase 3 studies of Sofpironium Bromide showed very high statistical significance for the treatment of primary axillary hyperhidrosis. In the US alone, there are approximately […]

Capital Raise Update

September 12, 2022 in , , /by

Botanix has announced it has now closed the first tranche of its anticipated $7.5 million placement to new and existing institutional and sophisticated investors. The second tranche of the Placement is an issue of New Shares to Botanix directors, who have  committed to subscribe for a total of $0.5 million of New Shares, which is […]

$7.5m Capital Raise

September 2, 2022 in , , /by

Botanix has today announced it has received strong commitments to raise $7.5m through a placement to Australian and international institutions and sophisticated investors. Funds will support the development of the Company’s lead asset – Sofpironium Bromide (SB) – a novel dermatology asset with positive Phase 3 data to treat primary axillary hyperhidrosis, a medical condition […]